Abstract 1887P
Background
Palliative care patients experience chronic sorrow due to living loss such as impairment in bodily functions, inability to carry out daily life, and meaninglessness due to impending death. Logotherapy was shown to be an effective method to cope with end-of-life related distress. The aim of this study was to investigate effectiveness of logotherapy on chronic sorrow, dignity, and meaning in life on palliative care patients.
Methods
This randomized-controlled study was conducted between September 2021-June 2023 in medical and gynecological oncology clinics of a university hospital, with 58 adult advanced cancer patients requiring palliative care. Participants were assigned to either intervention (n=29) or control (n=29) group by simple randomization via a computer program. Participants, ≥18 years old, having advanced solid cancer, aware of their diagnosis, having no communication problem or mental disorder, with a life expectancy over 6 months and Palliative Performance Scale score ≥%50, and verbally expressing to experience chronic sorrow were included. Data were collected with demographic form, Patient Dignity Inventory (PDI), Prolonged Grief Disorder Scale-Patient Form (PGD-PF), presence of meaning (MIL-PM) and search for meaning (MIL-SM) subdimensions of Meaning in Life (MIL) Questionnaire. Data were collected on admission, at the 4th and 8th weeks. Intervention group received logotherapy, lasting about of 45 minutes, 2 days a week for 4 weeks. Control group received routine care.
Results
The mean scores of PDI (p=0.01), PGD-PF (p=0.01) and MIL-SM (p=0.11) were lower in the intervention group, while MIL-PM was higher (p=0.02). Within group analysis showed a decrease in PDI (p<0.01), PGD-PF (p=0.01), MIL-SM (p=0.02), and increase in MIL-PM (p<0.01) in the intervention group while mean scores of PDI (p=0.01), PGD-PF (p=0.01), MIL-SM (p=0.04), and MIL-PM (p=0.05) decreased in control group.
Conclusions
Logotherapy was found effective on decreasing sorrow and dignity related distress of palliative care patients, while increasing finding meaning in life.
Clinical trial identification
NCT05129059.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1852P - The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Presenter: Poorni Jaganathan
Session: Poster session 12
1853P - Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Presenter: David Gandara
Session: Poster session 12
1854P - Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study
Presenter: Kadriye Baskurt
Session: Poster session 12
1855P - Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ)
Presenter: Carolina Navas
Session: Poster session 12
1856P - Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study
Presenter: Javier López Robles
Session: Poster session 12
1857P - Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS)
Presenter: Jerold Loh
Session: Poster session 12
1858P - Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies
Presenter: Nikolaos Tsoukalas
Session: Poster session 12
1860P - The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia
Presenter: Yuanping Hsia
Session: Poster session 12
1861P - Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
Presenter: Manuel Sanchez Canovas
Session: Poster session 12
1862P - A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors
Presenter: Weiwen Zhou
Session: Poster session 12